Plant Comparison
Perforate St John’s-wort vs Chaga
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Perforate St John’s-wort and Chaga: they share 6 indicated uses (arthritis / joint pain, cold & flu, infection (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Perforate St John’s-wort | Chaga | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cold & flu | 1/10 | 1/10 | Comparable evidence |
| Infection (general) | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Wounds | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.
Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.
Antioxidant flavonoids contributing to overall activity.
Chaga's dark colour comes from melanin-like pigments; it also concentrates betulinic-acid-type triterpenes absorbed from its birch host, associated with antioxidant and anticancer research interest.
Immunomodulatory polysaccharides contributing to the traditional tonic and immune-support use.
Antioxidant phenolics contributing to chaga's free-radical-scavenging activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anticancer action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Chaga-derived 3,4-DHBA protected against Parkinson's-related neurotoxicity (preclinical).
Chaga polysaccharide lowered lipids in vivo and in vitro.
Safety, Cautions & Contraindications
Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.
Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).
Autoimmune conditions: Chaga can stimulate parts of the immune system—people with autoimmune diseases should be cautious.Blood thinners: Chaga contains compounds that may affect clotting—avoid large doses if on anticoagulants.Blood sugar meds: May slightly lower glucose—monitor if taking diabetes medication.Pregnancy & breastfeeding: Limited safety data—best avoided unless guided by a professional.Quality matters: Wild-harvested Chaga can accumulate heavy metals from trees and soil—source from reputable suppliers.
External Ids
Botanical Description
Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]
Parasitic wood-decay fungus (not a true plant) that grows almost entirely inside the trunk of living birch trees, visible externally only as a hard, black, cracked, charcoal-like mass (a sclerotium, sometimes called a 'conk') erupting through the bark. Unlike typical mushrooms, chaga has no true cap, gills or stem; its fertile spore-producing surface develops later, hidden beneath the bark after the tree dies.[1]
Habitat
Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]
Grows almost exclusively as a parasite on living birch trees in cold, northern temperate and boreal forests of Europe, Russia, North America and Asia.[1]
Harvesting
The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]
The hard black external mass (conk) is chopped or broken away from the living birch trunk, ideally without killing the tree, then dried and broken into pieces or ground for use; sustainable harvesting (leaving part of the conk to regrow) is recommended given the fungus's slow growth.
Traditional Uses
St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]
Chaga has a long traditional use in Russian, Siberian, Baltic and Scandinavian folk medicine as a tonic remedy for digestive complaints, immune support and general vitality, traditionally taken as a dark, tea-like decoction; this traditional tonic reputation is now studied for its antioxidant, immunomodulatory and anti-inflammatory properties.[1, 4]
Preparations
Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.
Dosage
Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.
Not documented
Drug Class Interactions
Not documented
References
Pairings
St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]
St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]
St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]
St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]
Not documented
Lookalikes Review
References & Sources
- Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
https://doi.org/10.1016/j.jad.2016.12.048 - Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
https://doi.org/10.1007/s00210-022-02229-z - Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
https://doi.org/10.1016/S0140-6736(99)06457-0 - Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
https://doi.org/10.22038/IJBMS.2022.65112.14338 - Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
https://doi.org/10.1016/j.phymed.2024.155847 - Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
https://doi.org/10.3389/fpls.2016.01004 - Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
https://doi.org/10.1002/ptr.5050 - Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
https://doi.org/10.1016/j.jep.2010.07.034 - Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
https://doi.org/10.1016/j.lfs.2004.04.005 - Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
https://doi.org/10.3109/13697137.2013.861814 - Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
https://doi.org/10.2165/00003088-200645050-00002 - Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
https://doi.org/10.1055/s-2001-15467 - Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
https://doi.org/10.1038/sj.mp.4000557 - Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
https://doi.org/10.2174/1568026033392589 - Linde, K. et al (2008) 'St John'. Traditional / reference
https://scholar.google.com/scholar?q=St%20John - Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
https://doi.org/10.1177/0269881104042632 - Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
https://doi.org/10.2165/11317010-000000000-00000 - Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
https://doi.org/10.1208/s12248-009-9146-8 - Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
https://doi.org/10.1111/bph.14936 - Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
https://doi.org/10.1016/S0140-6736(99)05712-8 - Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
https://doi.org/10.1345/aph.10088 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
https://doi.org/10.1046/j.1365-2125.2003.02005.x - Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
https://doi.org/10.1053/cp.1999.v66.a101944 - Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
https://doi.org/10.1093/jnci/94.16.1247 - Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
https://doi.org/10.1592/phco.24.16.1508.50958 - Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
https://doi.org/10.5414/cpp42139 - Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
https://doi.org/10.3390/ph19030399
- Camilleri, E., Blundell, R., Baral, B., Karpinski, T.M. et al (2024) 'A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms', Heliyon, 10(15), pp. e35638. doi:10.1016/j.heliyon.2024.e35638 Traditional / reference
https://doi.org/10.1016/j.heliyon.2024.e35638 - Lu, Y., Jia, Y., Xue, Z., Li, N. et al (2021) 'Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application', Polymers (Basel), 13(9), pp. 1441. doi:10.3390/polym13091441 Traditional / reference
https://doi.org/10.3390/polym13091441 - Kobus, Z., Krzywicka, M., Blicharz-Kania, A., Bosacka, A. et al (2024) 'Impact of Incorporating Dried Chaga Mushroom (Inonotus obliquus) into Gluten-Free Bread on Its Antioxidant and Sensory Characteristics', Molecules, 29(16), pp. 3801. doi:10.3390/molecules29163801 Preclinical
https://doi.org/10.3390/molecules29163801 - Szychowski, K.A., Skora, B., Pomianek, T. and Gminski, J (2020) 'Inonotus obliquus - from folk medicine to clinical use', Journal of Traditional and Complementary Medicine, 11(4), pp. 293-302. doi:10.1016/j.jtcme.2020.08.003 Meta-analysis / review
https://doi.org/10.1016/j.jtcme.2020.08.003 - Javed, S., Mitchell, K., Sidsworth, D., Sellers, S.L., Reutens-Hernandez, J., Massicotte, H.B., Egger, K.N., Lee, C.H. and Payne, G.W (2019) 'Inonotus obliquus attenuates histamine-induced microvascular inflammation', PLoS One, 14(8), pp. e0220776. doi:10.1371/journal.pone.0220776 Preclinical
https://doi.org/10.1371/journal.pone.0220776 - Zou, C., Hou, Z., Bai, M., Guo, R., Lin, B., Wang, X., Huang, X. and Song, S (2020) 'Highly modified steroids from Inonotus obliquus', Organic & Biomolecular Chemistry, 18(20), pp. 3908-3916. doi:10.1039/d0ob00474j Preclinical
https://doi.org/10.1039/d0ob00474j - Zhong, X.H., Ren, K., Lu, S.J., Yang, S.Y. and Sun, D.Z (2009) 'Progress of research on Inonotus obliquus', Chinese Journal of Integrative Medicine, 15(2), pp. 156-160. doi:10.1007/s11655-009-0156-2 Meta-analysis / review
https://doi.org/10.1007/s11655-009-0156-2 - Burmasova, M.A., Utebaeva, A.A., Sysoeva, E.V. and Sysoeva, M.A (2019) 'Melanins of Inonotus obliquus: bifidogenic and antioxidant properties', Biomolecules, 9(6), pp. 248. doi:10.3390/biom9060248 Preclinical
https://doi.org/10.3390/biom9060248 - Sun, Y., Deng, X., Li, Z., Dong, Y., Jiang, W., Ma, Y., Zhou, W., Zhu, T., Wang, G., Liu, S. and Hu, B (2022) 'Polysaccharide derived from Inonotus obliquus inhibits lipopolysaccharide-induced acute endometritis in mice', American Journal of Translational Research, 14(11), pp. 8332-8342. Preclinical
https://scholar.google.com/scholar?q=Polysaccharide%20derived%20from%20Inonotus%20obliquus%20inhibits%20lipopolysaccharide-induced%20acute%20endometritis%20in%20mice - Ishfaq, P.M., Mishra, S., Mishra, A., Ahmad, Z., Gayen, S., Jain, S.K., Tripathi, S. and Mishra, S.K (2022) 'Inonotus obliquus aqueous extract prevents histopathological alterations in liver induced by environmental toxicant Microcystin', Current Research in Pharmacology and Drug Discovery, 3, pp. 100118. doi:10.1016/j.crphar.2022.100118 Preclinical
https://doi.org/10.1016/j.crphar.2022.100118 - Peng, A., Liu, S., Fang, L., Zhu, Z., Zhou, Y., Yue, S., Ma, Z., Liu, X., Xue, S., Qiu, Y. and Qi, R (2022) 'Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis', European Journal of Pharmacology, 921, pp. 174841. doi:10.1016/j.ejphar.2022.174841 Preclinical
https://doi.org/10.1016/j.ejphar.2022.174841 - Zhang, Y., Liu, Q., Sun, Y. and Jiang, J (2023) 'Inonotus obliquus sclerotia epidermis were different from internal tissues in compound composition, antioxidant activity, and associated fungi', FEMS Microbiology Letters, 370, pp. fnad126. doi:10.1093/femsle/fnad126 Preclinical
https://doi.org/10.1093/femsle/fnad126 - Yu, S., Lai, Z., Xue, H., Zhu, J., Yue, G., Wang, J. and Jin, L.H (2024) 'Inonotus obliquus aqueous extract inhibits intestinal inflammation and insulin metabolism defects in Drosophila', Toxicology Mechanisms and Methods, 34(9), pp. 970-984. doi:10.1080/15376516.2024.2368795 Preclinical
https://doi.org/10.1080/15376516.2024.2368795 - Wold, C.W. and Christopoulos, P. and Arias, M. and Dzovor, D.E. and Øynebråten, I. and Corthay, A. and Inngjerdingen, K.T (2024) 'Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity', Communications Biology. doi:10.1038/s42003-024-05853-y Preclinical
https://doi.org/10.1038/s42003-024-05853-y - Li, J. and Qu, C. and Li, F. and Chen, Y. and Zheng, J. and Xiao, Y. and Jin, Q. and Jin, G. and Huang, X. and Jin, D (2021) 'Inonotus obliquus Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome', Frontiers in Pharmacology. doi:10.3389/fphar.2020.621835 Preclinical
https://doi.org/10.3389/fphar.2020.621835 - Wold, C.W. and Gerwick, W.H. and Wangensteen, H. and Inngjerdingen, K.T (2020) 'Bioactive triterpenoids and water-soluble melanin from Inonotus obliquus (Chaga) with immunomodulatory activity', Journal of Functional Foods. doi:10.1016/j.jff.2020.104025 Preclinical
https://doi.org/10.1016/j.jff.2020.104025 - Kim, J. and Yang, S. and Hwang, A.Y. and Cho, H. and Hwang, K.T (2020) 'Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines', Molecules. doi:10.3390/molecules25184066 Preclinical
https://doi.org/10.3390/molecules25184066 - Duru, K.C. and Kovaleva, E.G. and Данилова, И.Г. and Bijl, P.V.D (2019) 'The pharmacological potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies', Phytotherapy Research. doi:10.1002/ptr.6384 Preclinical
https://doi.org/10.1002/ptr.6384 - Hu, Y. and Teng, C. and Yu, S. and Wang, X. and Liang, J. and Bai, X. and Dong, L. and Song, T. and Yu, M. and Qu, J (2017) 'Inonotus obliquus polysaccharide regulates gut microbiota of chronic pancreatitis in mice', AMB Express. doi:10.1186/s13568-017-0341-1 Preclinical
https://doi.org/10.1186/s13568-017-0341-1 - Chou, Y. and Kan, W. and Chang, C. and Peng, Y. and Wang, H. and Yu, W. and Cheng, Y. and Jhang, Y. and Liu, H. and Chuu, J (2016) 'Renal Protective Effects of Low Molecular Weight of Inonotus obliquus Polysaccharide (LIOP) on HFD/STZ-Induced Nephropathy in Mice', International Journal of Molecular Sciences. doi:10.3390/ijms17091535 Preclinical
https://doi.org/10.3390/ijms17091535 - Arata, S. and Watanabe, J. and Maeda, M. and Yamamoto, M. and Matsuhashi, H. and Mochizuki, M. and Kagami, N. and Honda, K. and Inagaki, M (2016) 'Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice', Heliyon. doi:10.1016/j.heliyon.2016.e00111 Preclinical
https://doi.org/10.1016/j.heliyon.2016.e00111 - Lee, K.R. and Lee, J.S. and Kim, Y.R. and Song, I.G. and Hong, E.K (2014) 'Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-κB signaling pathway', Oncology Reports. doi:10.3892/or.2014.3103 Preclinical
https://doi.org/10.3892/or.2014.3103 - Song, F. and Liu, Y. and Kong, X. and Chang, W. and Song, G (2013) 'Progress on Understanding the Anticancer Mechanisms of Medicinal Mushroom: Inonotus Obliquus', Asian Pacific Journal of Cancer Prevention. doi:10.7314/apjcp.2013.14.3.1571 Preclinical
https://doi.org/10.7314/apjcp.2013.14.3.1571 - Gunjima, K. and Tomiyama, R. and Takakura, K. and Yamada, T. and Hashida, K. and Nakamura, Y. and Konishi, T. and Matsugo, S. and Hori, O (2013) '3,4‐Dihydroxybenzalacetone Protects Against Parkinson's Disease‐Related Neurotoxin 6‐OHDA Through Akt/Nrf2/Glutathione Pathway', Journal of Cellular Biochemistry. doi:10.1002/jcb.24643 Preclinical
https://doi.org/10.1002/jcb.24643 - Geng, Y. and Lu, Z. and Huang, W. and Xu, H. and Shi, J. and Xu, Z (2013) 'Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of Inonotus obliquus', Molecules. doi:10.3390/molecules18011150 Preclinical
https://doi.org/10.3390/molecules18011150 - Zhang, L. and Fan, C. and Liu, S. and Zang, Z. and Jiao, L. and Zhang, L (2011) 'Chemical composition and antitumor activity of polysaccharide from Inonotus obliquus', Journal of Medicinal Plants Research. doi:10.5897/jmpr.9000346 Preclinical
https://doi.org/10.5897/jmpr.9000346 - Choi, S. and Hur, S.J. and An, C.S. and Jeon, Y.H. and Jeoung, Y.J. and Bak, J.P. and Lim, B.O (2010) 'Anti-Inflammatory Effects ofInonotus obliquusin Colitis Induced by Dextran Sodium Sulfate', Journal of Biomedicine and Biotechnology. doi:10.1155/2010/943516 Preclinical
https://doi.org/10.1155/2010/943516 - Youn, M. and Kim, J. and Park, S. and Kim, Y. and Kim, S. and Lee, J.S. and Chai, K.Y. and Kim, H. and Cui, M. and So, H.S. and Kim, K. and Park, R (2008) 'Chaga mushroom (Inonotus obliquus ) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells', World Journal of Gastroenterology. doi:10.3748/wjg.14.511 Preclinical
https://doi.org/10.3748/wjg.14.511 - Nakajima, Y. and Sato, Y. and Konishi, T (2007) 'Antioxidant Small Phenolic Ingredients in Inonotus obliquus (persoon) Pilat (Chaga)', Chemical and Pharmaceutical Bulletin. doi:10.1248/cpb.55.1222 Preclinical
https://doi.org/10.1248/cpb.55.1222 - Kim, H. and Yoon, D. and Kim, C. and Shrestha, B. and Chang, W. and Lim, S. and Lee, W. and Han, S. and Lee, J. and Lim, M. and Kim, G. and Choi, S. and Song, W.O. and Sung, J. and Hwang, K (2007) 'Ethanol Extract of Inonotus obliquus Inhibits Lipopolysaccharide-Induced Inflammation in RAW 264.7 Macrophage Cells', Journal of Medicinal Food. doi:10.1089/jmf.2006.156 Preclinical
https://doi.org/10.1089/jmf.2006.156 - Mizuno, T. and Zhuang, C. and Abe, K. and Okamoto, H. and Kiho, T. and Ukai, S. and Leclerc, S. and Meijer, L (1999) 'Antitumor and Hypoglycemic Activities of Polysaccharides from the Sclerotia and Mycelia of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetideae)', International journal of medicinal mushrooms. doi:10.1615/intjmedmushr.v1.i4.20 Preclinical
https://doi.org/10.1615/intjmedmushr.v1.i4.20 - Su, L. and Xin, C. and Yang, J. and Dong, L. and Mei, H. and Dai, X. and Wang, Q (2022) 'A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus', International Journal of Biological Macromolecules. doi:10.1016/j.ijbiomac.2022.06.071 Preclinical
https://doi.org/10.1016/j.ijbiomac.2022.06.071 - Yang, M. and Hu, D. and Cui, Z. and Li, H. and Man, C. and Jiang, Y (2021) 'Lipid-Lowering Effects of Inonotus obliquus Polysaccharide In Vivo and In Vitro', Foods. doi:10.3390/foods10123085 Preclinical
https://doi.org/10.3390/foods10123085 - Wang, J. and Hu, W. and Li, L. and Huang, X. and Liu, Y. and Wang, D. and Teng, L (2017) 'Antidiabetic activities of polysaccharides separated from Inonotus obliquus via the modulation of oxidative stress in mice with streptozotocin-induced diabetes', PLoS ONE. doi:10.1371/journal.pone.0180476 Preclinical
https://doi.org/10.1371/journal.pone.0180476 - Giridharan, V.V. and Thandavarayan, R.A. and Konishi, T (2011) 'Amelioration of scopolamine induced cognitive dysfunction and oxidative stress by Inonotus obliquus– a medicinal mushroom', Food & Function. doi:10.1039/c1fo10037h Preclinical
https://doi.org/10.1039/c1fo10037h - Lee, J. and Hyun, C (2014) 'Insulin‐Sensitizing and Beneficial Lipid‐Metabolic Effects of the Water‐Soluble Melanin Complex Extracted from Inonotus obliquus', Phytotherapy Research. doi:10.1002/ptr.5131 Preclinical
https://doi.org/10.1002/ptr.5131 - Kim, Y (2005) 'Immunomodulatory Activity of the Water Extract from Medicinal MushroomInonotus obliquus', Mycobiology. doi:10.4489/myco.2005.33.3.158 Preclinical
https://doi.org/10.4489/myco.2005.33.3.158 - Géry, A., Dubreule, C., André, V., Rioult, J.P., Bouchart, V., Heutte, N., Eldin de Pécoulas, P., Krivomaz, T. and Garon, D (2018) 'Chaga (Inonotus obliquus), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B)', 17(3), pp. 832--843. doi:10.1177/1534735418757912 Traditional / reference
https://doi.org/10.1177/1534735418757912 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Shashkina, M.Ya., Shashkin, P.N. and Sergeev, A.V (2006) 'Chemical and medicobiological properties of chaga', 40(10), pp. 560--568. Traditional / reference
https://scholar.google.com/scholar?q=Chemical%20and%20medicobiological%20properties%20of%20chaga - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.